

Editor  
World Journal of Clinical Cases  
Sylvain G Bourgoin

September, 22, 2020

Dear Editor:

Can the authors speculate a bit on the mechanism of ROS production by those non-activated segmented cells (i.e., the impact of azacytidine therapy on glycolysis)?

Thank you for your important suggestion.  
We added the sentences in discussion section as below.

Li et al reported that shift to a more glycolytic metabolism causes ROS decrease in cancer cells. We speculate that the increase of glycolysis after azacitidine treatment may affect the ROS decrease in MDS cells including neutrophils. Further examination will be required to evaluate this mechanism.

We are looking forward to a rapid and favorable review of our manuscript and its consideration for publication as a report in World Journal of Clinical Cases.

Sincerely yours,

Naomi Shimizu, M.D., Ph.D.  
Department of Hematology  
Toho University Sakura Medical Center  
564-1 Shimoshizu, Sakura-City, Chiba  
285-8741, Japan